leisure time -WSS

leisure time

author：comprehensive 2025-09-04 04:25:17 - browse：5

Scientist pipetting in a biotech lab -- biotech coverage from STAT — A researcher working in the lab at Crinetics Pharmaceuticals in San Diego. Courtesy Crinetics

SAN DIEGO — Crinetics Pharmaceuticals announced on Sunday that its experimental drug for acromegaly, a rare and serious hormonal disorder, succeeded in a late-stage trial, bringing the San Diego biotech a step closer to applying for Food and Drug Administration approval — and entry into a crowded market with blockbuster therapies sold by pharma giants.

In the Phase 3 study, dubbed PATHFNDR-1, nearly 60 patients were randomly assigned to receive a placebo or a daily dose of paltusotine, an oral medicine designed to lower levels of growth hormone, which is produced in excess by people with acromegaly. After 36 weeks of treatment, 25 of the 30 patients given the drug had growth-factor levels that were within the normal range compared to just 1 of 28 participants who took the placebo, a difference that was statistically significant. Researchers also found that the treatment’s side effects were mild overall.

Crinetics plans to file for FDA approval if it gets positive results from a second, ongoing Phase 3 trial of the drug in acromegaly patients. The biotech expects results from that study, known as PATHFNDR-2, by the first quarter of next year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Hollywood unions extend contract negotiations for actors

knowledge

WSS

First Opinion on colorectal cancer screening: letter and response

The high cost of giving birth even with insurance

Trump demands the U.S. pay no more for drugs than other countries … again

UnitedHealth, in a surprise, takes aim at Steward’s physician group

Anesthesiologist group: stop taking Ozempic before surgery

UnitedHealth, in a surprise, takes aim at Steward’s physician group

focus

leisure time

entertainment

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Alzheimer's risk factor APOE4 may be a distinct form of the disease

Jerome Adams on the need for new antivirals for Covid

Bird flu reported in person exposed to presumably infected cattle

In Memoriam: Notable people who died in 2023

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Walensky prepares to leave CDC — and Congress — behind

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Heart attack and stroke risk calculators need revising

Supreme Court strikes down use of affirmative action

Wikipedia

UnitedHealth, in a surprise, takes aim at Steward’s physician group

After affirmative action ruling, medical educators look to 'holistic review'

Republican states more likely to report Covid vaccine side effects

U.K. decision on ALS drug has neurologists, advocates up in arms

Medical records are filled with copy

Guidelines to prevent youth baseball injuries need more muscle

explore

hotspot

knowledge

knowledge